XCancer

A Pilot Study of Total-body PET Using FDA-approved Radiotracers Beyond 18F-FDG

Description:

The purpose of this research study is to test new ways to improve the usefulness of the world's first total-body positron emission tomography (PET)/computed tomography (CT) scanner (EXPLORER) by collecting data from PET scans using one of three different imaging agents: 18F-PSMA; 18F-FES; or, 68Ga DOTATATE. These imaging agents are approved by the FDA to be used for patients diagnosed with prostate cancer (18F-PSMA), neuroendocrine tumor (68Ga DOTATATE), or breast cancer (18F-FES).

Sponsor:

University of California, Davis

Contacts:

Lorenzo Nardo, MD (PRINCIPAL_INVESTIGATOR)

Government Study Link:

NCT05160480 - Click here to see study on

ClinicalTrials.gov

PSMA-1007

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

DOTATATE

Isotope(s):
Target(s):
  • SSTR2
Ligand Class: Peptides
Chelator: DOTA

FES

Isotope(s):
Target(s):
  • Estrogen Receptor
Ligand Class: Small Molecules
Inclusion
  • Persons \> 18 yo suspicious for or diagnosed with somatostatin receptor positive neuroendocrine tumors (NETs)
  • Persons \>18 yo with suspected prostate cancer metastasis
  • Prior imaging study (CT, and/or MRI and/or Bone scan and/or Fluciclovine scan) suspicious for metastatic disease, obtained within 4 months from the research scan date. 68Ga DOTATATE (n=3) or 64Cu-DOTATATE (n=3)Inclusion Criteria:
  • Prior DOTATATE PET/CT scan suspicious for tumor obtained not earlier than 4 months from the research scan date.
Exclusion

Exclusion Criteria Not Yet Provided